These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3608349)

  • 1. A urinary metabolite ratio that reflects systemic caffeine clearance.
    Campbell ME; Spielberg SP; Kalow W
    Clin Pharmacol Ther; 1987 Aug; 42(2):157-65. PubMed ID: 3608349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
    Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
    Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.
    Campbell ME; Grant DM; Inaba T; Kalow W
    Drug Metab Dispos; 1987; 15(2):237-49. PubMed ID: 2882985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
    Fuhr U; Rost KL
    Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary excretion of an uracilic metabolite from caffeine by rat, monkey and man.
    Latini R; Bonati M; Marzi E; Garattini S
    Toxicol Lett; 1981 Jan; 7(3):267-72. PubMed ID: 7222102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.
    Petersen MS; Halling J; Damkier P; Nielsen F; Grandjean P; Weihe P; Brøsen K
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1041-8. PubMed ID: 17089110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
    Rost KL; Roots I
    Clin Pharmacol Ther; 1994 Apr; 55(4):402-11. PubMed ID: 8162667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH; Nierenberg DW; Bresnick E
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HPLC determination of five caffeine metabolites].
    Lu JF; Yi T; Cao XM; Zhuo HT; Lin SS
    Yao Xue Xue Bao; 1997 Aug; 32(8):607-11. PubMed ID: 11596311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
    Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
    Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping.
    Tang BK; Kadar D; Qian L; Iriah J; Yip J; Kalow W
    Clin Pharmacol Ther; 1991 Jun; 49(6):648-57. PubMed ID: 2060254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine excretion of caffeine and select caffeine metabolites is common in the U.S. population and associated with caffeine intake.
    Rybak ME; Sternberg MR; Pao CI; Ahluwalia N; Pfeiffer CM
    J Nutr; 2015 Apr; 145(4):766-74. PubMed ID: 25833779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette smoking and theophylline clearance and metabolism.
    Grygiel JJ; Birkett DJ
    Clin Pharmacol Ther; 1981 Oct; 30(4):491-6. PubMed ID: 7285483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human N-acetylation genotype determination with urinary caffeine metabolites.
    Kilbane AJ; Silbart LK; Manis M; Beitins IZ; Weber WW
    Clin Pharmacol Ther; 1990 Apr; 47(4):470-7. PubMed ID: 2328555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.